What is the significance of the NRDL inclusion for BeOne Medicines?

The inclusion of BeOne Medicines' oncology drugs in the NRDL is highly significant as it makes these treatments more affordable and accessible to a larger patient population in China. This is expected to drive substantial commercial growth and improve the company's market position within the Chinese oncology sector.

Which specific drugs were added to the NRDL?

The three drugs included are tislelizumab (an internally-developed anti-PD-1 antibody), BRUKINSA® (zanubrutinib, an internally-developed BTK inhibitor), and XGEVA® (120-mg denosumab), which is part of a strategic collaboration with Amgen.

How will this impact BeOne Medicines' revenue?

The NRDL listing is a positive catalyst for revenue. By reducing out-of-pocket costs for patients, it is expected to lead to increased prescription volumes and sales for tislelizumab, BRUKINSA®, and XGEVA® in China, thereby boosting the company's overall financial performance.

Does this NRDL inclusion apply to other markets outside of China?

This specific announcement pertains to the inclusion in China's National Reimbursement Drug List (NRDL). Reimbursement status and drug lists vary significantly by country, and further information would be needed to understand the impact in other global markets.

ONC/BEIGF 8-K SEC Disclosure

Summary

BeOne Medicines Ltd. (ONC) announced a significant development on December 28, 2020, regarding the inclusion of three of its key oncology medicines in China's National Reimbursement Drug List (NRDL). This inclusion, effective immediately, is a crucial step for the company as it facilitates broader patient access and enhances the commercial potential of these important therapies within the vast Chinese market. The NRDL listing is a strong indicator of government support and recognition of the clinical value of these innovative treatments.

Key Highlights

1Three BeOne Medicines oncology drugs included in the updated China National Reimbursement Drug List (NRDL).
2The included drugs are tislelizumab (anti-PD-1 antibody), BRUKINSA® (zanubrutinib, BTK inhibitor), and XGEVA® (denosumab).
3Tislelizumab is internally developed by BeOne Medicines.
4BRUKINSA® (zanubrutinib) is also internally developed by BeOne Medicines.
5XGEVA® is part of a strategic collaboration with Amgen.
6The NRDL inclusion is expected to significantly improve market access and patient affordability in China.
7This development positions BeOne Medicines for substantial revenue growth in the Chinese oncology market.

BeOne Medicines Ltd. 8-K Report, Corporate Update (Dec 28, 2020)

Summary

Key Highlights

Frequently Asked Questions